RETRACTED: Arginase II - a new target in the development of endothelium protectors
| Autor: | V. I. Yakushev, M. V. Pokrovsky, E. A. Beskhmelnitsyna, O. V. Myasishcheva, A. S. Litvinova, I. I. Krivoshapova, S. A. Demchenko |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Регуляторные исследования и экспертиза лекарственных средств, Vol 0, Iss 1, Pp 26-30 (2018) |
| Druh dokumentu: | article |
| ISSN: | 3034-3062 3034-3453 |
| Popis: | RETRACTED ARTICLEThe article describes arginase’s role in pathogenesis of endothelial dysfunction and a number of cardio-vascular diseases. Arginase catalyzes the hydrolysis of L-arginine, the substrate for nitric oxide synthesis, to L-ornithine and urea. Two isoforms of arginase were found in the human organism. Arginase I is located in the cells cytoplasm and is predominantly expressed in the liver. Arginase II is a mitochondrial protein that is expressed in the kidney, prostatic gland and vascular wall. Arginase II hydrolyzes L-arginine, thereby reducing the synthesis of nitric oxide and leading to the development of endothelial dysfunction and a number of cardio-vascular disorders. Arginase is a promising pharmacological target in the treatment of endothelial dysfunction and a number of cardio-vascular diseases, though the development of highly-selective arginase II inhibitors is still a difficult task. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|